Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

Campbell, Robert; Chong, Geoffrey; Hawkes, Eliza A.

doi:10.3390/jcm7040062

Open AccessFeature PaperReview

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

by

Robert Campbell

^1,2,

Geoffrey Chong

^1,3,4 and

Eliza A. Hawkes

^1,5,6,*

¹

Department of Medical Oncology and Clinical Haematology, Olivia Newton-John Cancer Research Institute, Austin Health, Heidelberg, VIC 3084, Australia

²

Bendigo Cancer Centre, Bendigo Health, Bendigo, VIC 3084, Australia

³

Department of Oncology, Northern Hospital, Melbourne, VIC 3084, Australia

⁴

Department of Medical Oncology, Ballarat Health Services, Ballarat, VIC 3084, Australia

⁵

Department of Medical Oncology, Eastern Health, Melbourne, VIC 3084, Australia

⁶

Eastern Health, Monash University Clinical School, Melbourne, VIC 3084, Australia

^*

Author to whom correspondence should be addressed.

J. Clin. Med. 2018, 7(4), 62; https://doi.org/10.3390/jcm7040062

Submission received: 31 December 2017 / Revised: 18 February 2018 / Accepted: 6 March 2018 / Published: 21 March 2018

(This article belongs to the Section Hematology)

Download

Browse Figures

Versions Notes

Abstract

Bruton’s tyrosine kinase (BTK) is a critical terminal enzyme in the B-cell antigen receptor (BCR) pathway. BTK activation has been implicated in the pathogenesis of certain B-cell malignancies. Targeting this pathway has emerged as a novel target in B-cell malignancies, of which ibrutinib is the first-in-class agent. A few other BTK inhibitors (BTKi) are also under development (e.g., acalabrutinib). While the predominant action of BTKi is the blockade of B-cell receptor pathway within malignant B-cells, increasing the knowledge of off-target effects as well as a potential role for B-cells in proliferation of solid malignancies is expanding the indication of BTKi into non-hematological malignancies. In addition to the expansion of the role of BTKi monotherapy, combination therapy strategies utilizing ibrutinib with established regimens and combination with modern immunotherapy compounds are being explored.

Keywords: ibrutinib; Bruton’s tyrosine kinase; solid tumors

Share and Cite

MDPI and ACS Style

Campbell, R.; Chong, G.; Hawkes, E.A. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. J. Clin. Med. 2018, 7, 62. https://doi.org/10.3390/jcm7040062

AMA Style

Campbell R, Chong G, Hawkes EA. Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. Journal of Clinical Medicine. 2018; 7(4):62. https://doi.org/10.3390/jcm7040062

Chicago/Turabian Style

Campbell, Robert, Geoffrey Chong, and Eliza A. Hawkes. 2018. "Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies" Journal of Clinical Medicine 7, no. 4: 62. https://doi.org/10.3390/jcm7040062

APA Style

Campbell, R., Chong, G., & Hawkes, E. A. (2018). Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies. Journal of Clinical Medicine, 7(4), 62. https://doi.org/10.3390/jcm7040062

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI